Categories
Change Password!
Reset Password!
European Headache Federation documented the evidence-based and expert-based guidelines on the usage of Monoclonal antibodies for migraine prevention.
The monoclonal antibodies acting on the calcitonin gene-related peptide are the novel drugs which can be suggested for migraine prevention, as explained in 'The Journal of Headache and Pain'.
Four
monoclonal antibodies have been developed, i.e., 1 targeting the
calcitonin gene-related peptide receptor (erenumab) and 3 targeting
the calcitonin gene-related peptide (eptinezumab, fremanezumab, and
galcanezumab). The European Headache Federation (EHF) focused on
providing an evidence-based and expert-based guideline explaining the
use of the monoclonal antibodies acting on the calcitonin
gene-related peptide to prevent migraine.
This guideline was made
by using the Grading of Recommendation, Assessment, Development, and
Evaluation (GRADE) approach. The working group recognised suitable
questions, executed systematic review and analysis of the literature,
evaluated the quality of available evidence, and composed the
recommendations. Expert opinion should be used where the GRADE
approach was not applicable.
Simona Sacco et al. found low to
high-quality evidence supporting eptinezumab, erenumab, fremanezumab,
and galcanezumab to recommend in patients suffering from episodic
migraine. Medium to high quality of evidence to recommend erenumab,
fremanezumab, and galcanezumab in patients with chronic migraine. For
various clinical questions, there was not enough evidence to provide
recommendations using the GRADE approach. The recommendations were
based on experts’ opinion.
"Real life data will be useful
to ameliorate the use of those drugs in clinical practice",
concluded the working group.
The Journal of Headache and Pain
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
Simona Sacco et al.
Comments (0)